Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations-Reference-Cited by-同舟云学术

Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations

Published:2021-07-23 Issue:12 Volume:81 Page:1381-1395
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Vrachatis Dimitrios A.^ORCID,Papathanasiou Konstantinos A.,Iliodromitis Konstantinos E.,Giotaki Sotiria G.,Kossyvakis Charalampos,Raisakis Konstantinos,Kaoukis Andreas,Lambadiari Vaia,Avramides Dimitrios,Reimers Bernhard,Stefanini Giulio G.,Cleman Michael,Giannopoulos Georgios,Lansky Alexandra,Deftereos Spyridon G.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40265-021-01565-3.pdf

Reference133 articles.

1. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2020;0:1–5.

2. McRae C, Kapoor A, Kanda P, Hibbert B, Davis DR. Systematic review of biological therapies for atrial fibrillation. Hear Rhythm. 2019;16:1399–407. https://doi.org/10.1016/j.hrthm.2019.03.021.

3. Gaita F, Scaglione M, Battaglia A, Matta M, Gallo C, Galatà M, et al. Very long-term outcome following transcatheter ablation of atrial fibrillation. Are results maintained after 10 years of follow up? Europace. 2018;20:443–50.

4. Kluger AY, Tecson KM, Lee AY, Lerma EV, Rangaswami J, Lepor NE, et al. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc Diabetol. 2019;18:1–13. https://doi.org/10.1186/s12933-019-0903-4.

5. Böhm M, Slawik J, Brueckmann M, Mattheus M, George JT, Ofstad AP, et al. Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. Eur J Heart Fail. 2020;22:126–35.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Sodium Glucose Co-Transporter 2 Inhibitors in Atrial Fibrillation: A Comprehensive Review;Journal of Clinical Medicine;2024-09-12

2. Recent Advances in Understanding the Molecular Mechanisms of SGLT2 Inhibitors in Atrial Remodeling;Current Issues in Molecular Biology;2024-08-31

3. Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists;Antioxidants;2023-12-20

4. Advances in the Management of Heart Failure with Reduced Ejection Fraction; The Role of SGLT2is, ARNI, Myotropes, Vericiguat, and Anti-inflammatory Agents: A Mini-review;Current Pharmaceutical Design;2023-02

5. Les inhibiteurs des SGLT2 réduisent le risque de fibrillation auriculaire, d’arythmies ventriculaires et de mort subite;Médecine des Maladies Métaboliques;2022-12